University of Illinois, Chicago

UIC scientists are developing novel antibiotics, antivirals, and cancer therapeutics—including bacterial ribosome-targeting depsipeptides, SARS-CoV-2 protease inhibitors, and macrophage-reprogramming HDAC6 inhibitors—to combat drug resistance and aggressive tumors. They are pairing these drug candidates with advanced delivery platforms such as pH-responsive nanocarriers, programmable RNA-gradient hydrogels, and transdermal breast-skin patches to minimize systemic toxicity and enable localized gene and small-molecule therapy. Together, these pipelines target urgent pharmaceutical markets in antimicrobial resistance, precision oncology, and next-generation biologics.

UIC researchers are unlocking new therapeutic avenues against therapy-resistant breast, lung, and pancreatic cancers by targeting ceramide signaling, tumor microenvironment reprogramming, and novel protein degraders. They are translating precision oncology into practice through AI-guided pharmacogenomics, circulating tumor cell technologies, and molecular tumor boards that address unmet clinical needs. By embedding equity-focused interventions and biomarker-driven strategies into drug discovery, the university is advancing commercially viable solutions for diverse patient populations and health systems.

University of Illinois Chicago researchers are advancing a diverse pipeline of anti-infectives, from ribosome-targeting natural-product antibiotics and broad-spectrum SARS-CoV-2 and influenza inhibitors to novel antitubercular agents that address escalating antimicrobial resistance. They complement drug discovery with AI-powered viral genomics, wastewater epidemiology, and data-driven stewardship programs that reduce hospital costs and optimize antibiotic use. The university also leads implementation-science efforts in HIV prevention and care, deploying telemedicine and community interventions to reach incarcerated and high-risk populations.

UIC researchers are engineering next-generation battery chemistries—including lithium-air, lithium-carbon dioxide, and sodium solid-state systems—through the George Crabtree Institute for Discovery and a $62.5 million DOE Energy Storage Research Alliance led by neighboring Argonne National Laboratory. Faculty with joint UIC–Argonne appointments bridge fundamental electrochemistry with applied device design, while spinoff AllCell Technologies (co-founded by UIC faculty) commercializes thermal-management solutions for lithium-ion battery packs. This deep integration with the national laboratory ecosystem and a growing battery-industry corridor positions UIC as a partner for companies developing safer, more sustainable energy storage at scale.

UIC engineers and clinicians are advancing wearable hemodynamic rings and cuffless blood-pressure monitors that enable continuous, at-home cardiovascular tracking for diabetes and heart-failure patients. They are also deploying machine-learning ECG screeners and predictive analytics for transcatheter valve procedures to catch disease earlier and optimize structural-heart interventions. Together, these technologies address real-world gaps in remote patient monitoring, maternal cardiovascular care, and health-equity markets.

University of Illinois Chicago researchers are advancing medical diagnostics through AI-powered imaging and computational pathology, including machine-learning models that detect uveal melanoma, classify retinal diseases via OCT, and identify predictive histology biomarkers for pancreatic and renal cancers. They are also developing point-of-care technologies—such as wearable hemodynamic rings, urine-based electrochemical biosensors for breast cancer, and microfluidic laser-scribed platforms—that enable rapid, low-cost screening in underserved populations. Combined with clinical NLP tools that reduce diagnostic errors and opioid misuse in emergency departments, this portfolio offers scalable commercial solutions for precision oncology, ophthalmology, and acute care.

University of Illinois Chicago engineers and clinicians are deploying artificial intelligence to interpret OCT, fundus, and ultrasound images for conditions such as diabetic retinopathy, uveal melanoma, and retinopathy of prematurity, reducing reliance on scarce specialists and enabling point-of-care screening. Complementing these AI tools, the team is advancing novel MRI and photoacoustic technologies that deliver non-invasive, high-resolution maps of tissue structure and blood flow for neurology, oncology, and dermatology applications. Together, these platforms address growing demand for faster, more accessible diagnostic workflows that lower costs and improve outcomes in both academic and community care settings.

University of Illinois Chicago researchers are harnessing large language models and multimodal machine learning to mine electronic health records, enabling earlier detection and precise phenotyping of Alzheimer’s, multiple sclerosis, and stroke. They are translating advances in brain imaging, blood-based biomarkers, and neuromodulation into practical tools for predicting motor recovery, guiding rehabilitation, and slowing neurodegenerative disease progression. This creates clear commercial pathways in digital diagnostics, remote patient monitoring, and precision neurology therapeutics.